On November 22, 2024, Deborah Autor, Director at Amneal Pharmaceuticals Inc (AMRX, Financial), sold 40,000 shares of the company, as reported in a SEC Filing. Following this transaction, the insider now owns 53,402 shares of the company.
Amneal Pharmaceuticals Inc (AMRX) is a pharmaceutical company that develops, manufactures, and distributes generic and specialty pharmaceutical products. The company operates in the United States and internationally, providing a wide range of products across various therapeutic areas.
Over the past year, Deborah Autor has sold a total of 78,000 shares and has not purchased any shares. The insider transaction history for Amneal Pharmaceuticals Inc indicates that there have been no insider buys in total over the past year, while there have been six insider sells during the same period.
On the day of the recent sale, shares of Amneal Pharmaceuticals Inc were trading at $8.35 each, giving the stock a market cap of $2.596 billion. The stock's GF Value is estimated at $2.51, resulting in a price-to-GF-Value ratio of 3.33. This suggests that the stock is significantly overvalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on three factors:
- Historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow that the stock has traded at.
- A GuruFocus adjustment factor based on the company’s past returns and growth.
- Future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
